ASND

Ascendis Pharma AS

128.18 USD
+0.54 (+0.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ascendis Pharma AS stock is up 4.38% since 30 days ago. The next earnings date is Sep 3, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 2 CALLs, 8 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 May 19:36 17 May, 2024 130.00 CALL 40 26
13 May 19:36 17 May, 2024 130.00 PUT 49 364
14 May 18:34 19 Jul, 2024 105.00 PUT 100 1
14 May 18:36 18 Oct, 2024 90.00 PUT 30 30
15 May 15:21 21 Jun, 2024 125.00 PUT 90 35
17 May 18:15 18 Oct, 2024 95.00 PUT 35 10
22 May 13:56 16 Aug, 2024 100.00 PUT 44 2
31 May 13:55 16 Aug, 2024 170.00 CALL 113 0
12 Jun 14:21 16 Aug, 2024 100.00 PUT 199 548
12 Jun 14:44 16 Aug, 2024 100.00 PUT 78 548

About Ascendis Pharma AS

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.